GLP-1 Studio
GLP-1 Studio Daily
What happened when Medicaid cut GLP-1s?
0:00
-3:19

What happened when Medicaid cut GLP-1s?

Plus insurance barriers, lung health and a four-target pill
A semaglutide injection pen on a plain background
Photo by Haberdoedas Photography on Pexels

Good morning! GLP-1 prescriptions for weight loss fell sharply in four states after Medicaid stopped paying for them. Also today: a JAMA summit report on insurance barriers to obesity care, 5.4% vs 13.5% lung disease with GLP-1s in systemic sclerosis, and an FDA filing for a weekly four-target obesity pill. Listen to me read them above, or read the key details below.

Daily Roundup:

  1. GLP-1 prescriptions for weight loss fell sharply in four states after Medicaid stopped paying for them (ReadMedia and Medical Daily)

  2. A JAMA summit report lays out insurance, drug and food policy steps to go with obesity medicines (AJMC)

  3. People with systemic sclerosis and obesity who took GLP-1s had fewer lung problems in a look back at health records (Healio)

  4. Ascletis asked the FDA to let it start testing a weekly pill aimed at four obesity targets (PR Newswire)


GLP-1 prescriptions for weight loss fell sharply in four states after Medicaid stopped paying for them

Key Details:

  • The study came out in JAMA on November 16, and a second-year student at Geisinger College's School of Medicine is one of its authors.

  • California, New Hampshire, Pennsylvania and South Carolina ended Medicaid coverage of GLP-1s for weight loss on January 1, 2026.

  • In those states, prescriptions per 100,000 people on Medicaid went from 2,914 in the last three months of 2025 to 421 in the first three months of 2026.

  • Pennsylvania had the steepest drop, at 95.5 percent.

Source: ReadMedia and Medical Daily


A JAMA summit report lays out insurance, drug and food policy steps to go with obesity medicines

Key Details:

  • The report says the insurance system discourages obesity treatment by not covering it or by requiring heavy prior authorization.

  • It says the Medicare GLP-1 Bridge and a Medicaid program called BALANCE could be expanded if they work.

  • The authors also called for stronger enforcement against compounded copies of FDA-approved drugs when there is no shortage.

  • They wrote, "no single intervention will be enough."

Source: AJMC


People with systemic sclerosis and obesity who took GLP-1s had fewer lung problems in a look back at health records

Key Details:

  • Researchers compared 1,578 pairs of patients who did or did not use GLP-1s, and presented the results at ACR Convergence in Orlando.

  • Over 10 years, 5.4 percent of GLP-1 users developed interstitial lung disease, compared with 13.5 percent of non-users.

  • Pulmonary hypertension, high blood pressure in the lungs, showed up in 6.5 percent of users and 15.1 percent of non-users.

  • Dr. Aseed Mestarihi of the University of Central Florida said, "We acknowledge that these results are not practice changing, and that these are just hypothesis-generating."

Source: Healio


Ascletis asked the FDA to let it start testing a weekly pill aimed at four obesity targets

Key Details:

  • The Hong Kong-listed company filed an Investigational New Drug application, the request to begin human trials, for a pill code-named ASC36_37o FDC.

  • The tablet combines two drugs that act on the amylin, GLP-1, GIP and glucagon receptors.

  • In rat studies, the combination led to about 69 percent more weight loss than one of those drugs alone.

  • The company has also started a US phase one study of a related pill, ASC36o, with first data on how the drug moves through the body expected by the end of 2026.

Source: PR Newswire


Learn More

Amanda Bonello

This is a reader-supported publication, thank you so much for your support.

💖

Instagram · TikTok · LinkedIn


Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured.

Discussion about this episode

User's avatar

Ready for more?